Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2025-12-27 @ 6:31 PM
Study NCT ID:
NCT01401166
Status:
COMPLETED
Last Update Posted:
2017-03-06
First Post:
2011-07-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-10
Start Date Type:
None
Primary Completion Date:
2013-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-12
Completion Date Type:
ACTUAL
First Submit Date:
2011-07-22
First Submit QC Date:
None
Study First Post Date:
2011-07-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-02-09
Results First Submit QC Date:
None
Results First Post Date:
2015-06-08
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-01-19
Last Update Post Date:
2017-03-06
Last Update Post Date Type:
ACTUAL